openPR Logo
Press release

Leading Element Driving Change in the Alzheimer's Disease Diagnostic Market in 2025: Impact Of Chronic Disease Growth On Alzheimer's Disease Diagnostic Industry Driver

03-25-2025 05:35 AM CET | Health & Medicine

Press release from: The Business Research Company

Alzheimer's Disease Diagnostic

Alzheimer's Disease Diagnostic

How Are the key drivers contributing to the expansion of the alzheimer's disease diagnostic market?
Improvements in healthcare infrastructure are expected to enhance the expansion of the allergic contact dermatitis market. Healthcare infrastructure refers to the medical facilities, technologies, and resources required for providing patient care and public health services. Factors such as increased government funding, growing healthcare demand, policy changes, and private sector investments contribute to its development. Enhanced healthcare infrastructure facilitates better allergic contact dermatitis management by improving access to specialized dermatological care, supporting early diagnosis and treatment, advancing allergen research, and promoting patient education through well-equipped facilities and trained professionals. For instance, in May 2023, the American Health Care Association, a US-based nonprofit, reported that the number of hospitals in the United States had increased to 6,129, reflecting a 0.591% rise from the previous year's 6,093. Thus, the expansion of healthcare infrastructure is positively impacting the allergic contact dermatitis market.

Get Your Alzheimer's Disease Diagnostic Market Report Here:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What growth opportunities are expected to drive the alzheimer's disease diagnostic market's CAGR through 2034?
The Alzheimer's disease diagnostic market has experienced rapid growth. It is projected to rise from $6.56 billion in 2024 to $7.28 billion in 2025, achieving a CAGR of 11%. Contributing factors in past growth include the rising prevalence of Alzheimer's disease and dementia, growing awareness of early diagnosis benefits, advancements in imaging technologies like MRI and PET scans, increased investments in neurodegenerative disease research, and government initiatives supporting Alzheimer's diagnostics.

The Alzheimer's disease diagnostic market size is anticipated to witness rapid expansion in the coming years. By 2029, it is projected to reach $10.91 billion, with a compound annual growth rate (CAGR) of 10.7%. The key factors driving this growth include the development of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized medicine and precision diagnostics, integration of AI and machine learning in diagnostic tools for early detection, growing adoption of digital health technologies for remote monitoring and diagnosis, and the expansion of healthcare infrastructure in emerging markets to improve accessibility. Significant trends in this period include the emergence of multi-modal diagnostic approaches combining imaging, biomarkers, and cognitive tests, a growing emphasis on point-of-care diagnostic solutions for faster results, development of wearable devices for continuous cognitive health monitoring, increasing collaborations between biotech companies and research institutions for innovative solutions, and growth in direct-to-consumer genetic testing for Alzheimer's risk assessment.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What are the emerging trends shaping the future of the alzheimer's disease diagnostic market?
In the Alzheimer's disease diagnostic market, major companies are working on blood-based biomarker tests expected to simplify the diagnostic process for Alzheimer's disease, reduce dependence on more invasive procedures, and improve access to timely treatment for patients. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched the LucentAD p-Tau 217 test, a blood-based biomarker for Alzheimer's pathology with clinical sensitivity and specificity. Traditional cerebrospinal fluid (CSF) biomarker approaches, such as positron emission tomography (PET) or lumbar puncture, are costly, invasive, and not widely accessible. Quanterix's test utilizes its ultra-sensitive SimoaÒ technology along with J&J Innovative Medicine's p-Tau 217 antibodies to provide excellent accuracy through a simpler process.

Which growth-oriented segments of the alzheimer's disease diagnostic market are leading the industry's development?
The alzheimer's disease diagnostic market covered in this report is segmented -

1) By Type: Triage, Diagnosis, Screening
2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests
3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:
1) By Triage: Cognitive Testing, Imaging Techniques
2) By Diagnosis: Biomarker Testing, Neuroimaging
3) By Screening: Neuropsychological Testing, Genetic Testing

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

What regions are leading the charge in the alzheimer's disease diagnostic market?
North America was the largest region in the alzheimer's disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer's disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the alzheimer's disease diagnostic market?
Major companies operating in the alzheimer's disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What Is Covered In The Alzheimer's Disease Diagnostic Global Market Report?

•Market Size Forecast: Examine the alzheimer's disease diagnostic market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the alzheimer's disease diagnostic market for a structured understanding.
•Key Players Overview: Analyze major players in the alzheimer's disease diagnostic market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the alzheimer's disease diagnostic market.
•Segment Contributions: Evaluate how different segments drive overall growth in the alzheimer's disease diagnostic market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the alzheimer's disease diagnostic market.
•Industry Challenges: Identify potential risks and obstacles affecting the alzheimer's disease diagnostic market.
•Competitive Landscape: Review strategic developments in the alzheimer's disease diagnostic market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leading Element Driving Change in the Alzheimer's Disease Diagnostic Market in 2025: Impact Of Chronic Disease Growth On Alzheimer's Disease Diagnostic Industry Driver here

News-ID: 3934404 • Views:

More Releases from The Business Research Company

Global Trends Analysis: How The Dental Practice Analytics Dashboards Market Is Rapidly Evolving
Global Trends Analysis: How The Dental Practice Analytics Dashboards Market Is R …
The dental practice analytics dashboards market is on track for significant expansion in the coming years, driven by the increasing use of data and technology in dental care management. As dental practices seek more efficient and patient-centered solutions, this market is set to grow rapidly, with new innovations and partnerships further enhancing its potential. Projected Market Size and Growth for Dental Practice Analytics Dashboards The market for dental practice analytics dashboards is
Datacenters Market Structure, Emerging Trends, And Leading Player Insights
Datacenters Market Structure, Emerging Trends, And Leading Player Insights
The datacenters market is on the verge of remarkable growth as digital transformation accelerates across multiple industries. Driven by cutting-edge technologies and changing business needs, this sector is set to expand rapidly in the coming years. Let's explore the current market size, the main companies involved, emerging trends, and the key segments shaping the future of datacenters globally. Steady Growth Forecast for the Datacenters Market by 2029 The global datacenters market is
Key Industry Players Strengthening Their Position In The Contract Food Service Management Market
Key Industry Players Strengthening Their Position In The Contract Food Service M …
The contract food service management sector is on track for notable expansion as consumer preferences and operational models evolve. Driven by rising health consciousness and technological advancements, this market is adapting to meet new demands while exploring innovative solutions. Let's delve into the current market size, key players, emerging trends, and major segments shaping the industry's future. Projected Market Value and Growth Dynamics in the Contract Food Service Management Market The contract
Global Trends Analysis: How The Cluster Of Differentiation (CD) 79a Antibody Market Is Rapidly Evolving
Global Trends Analysis: How The Cluster Of Differentiation (CD) 79a Antibody Mar …
The cluster of differentiation (CD) 79a antibody market is poised for substantial expansion in the coming years, driven by innovations and increasing demand within the healthcare and research sectors. This report offers a detailed overview of the market's size, key players, growth drivers, trends, and segmentation to provide a comprehensive understanding of future prospects. Projected Market Size and Growth Trajectory for the CD 79a Antibody Market The CD 79a antibody market is

All 5 Releases


More Releases for Alzheimer

Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928 Key Takeaways • Disease-modifying
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,